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Table 1 – Susceptibility proﬁle of Raoultella ornithinolytica.
Antibiotic Minimum inhibitory
concentration (MIC)
Susceptibility
Amikacin ≤8 S
Ampicillin–sulbactam >16/8 R
Aztreonam >16 R
Cefazolin >8 R
Cefepime >16 R
Cefoperazon–sulbactam >32/8 R
Cefoxitin >16 R
Ceftazidime 16 R
Ceftriaxone >4 R
Ciproﬂoxacin 1 S
Ertapenem >1 R
Gentamicin ≤2 S
Imipenem >8 R
Levoﬂoxacin ≤1 S
Meropenem >8 R
Piperacillin–tazobactam >64/4 R
Trimethoprim–sulfamethoxazole >4/76 R
S, susceptible; R, resistant.Dear Editor,
Raoultella ornithinolytica,  an encapsulated Gram-negative bac-
terium, is a member of the Enterobacteriaceae family. It rarely
causes invasive infections.1,2 There are underlying condi-
tions such as pathology of biliary system and malignancy
in most cases. Although the majority can recover with ade-
quate antibiotic therapy, some cases have a fatal outcome.2–4
A patient from our country with diabetic foot with ensuing
bacteremia had been reported.5 That case was successfully
treated by tigecycline.
A 37-year old male patient with relapsing acute lym-
phocytic leukemia (ALL) was admitted to the hematology
department for chemotherapy. He had been diagnosed 1.5
year before and had a history of bone marrow transplanta-
tion in the previous year. At ﬁrst day of FLAG (Fludarabine
30 mg/m2, cytosine arabinoside (Ara-C) 2 g/m2, granulocyte
colony stimulating factor (G-CSF) 5 g/kg/day) chemotherapy,
febrile neutropenia developed and piperacillin–tazobactam
4.5 g intravenously (iv) every 6 h was started. Fever was under
control in third day, but recurred after 12 days of treatment.
Amphotericin-B 3 mg/kg/day was started with monitoring of
galactomannan levels; based on the ﬁndings of high reso-
lution computed tomography (HRCT) antibiotic therapy was
switched to imipenem 500 mg  iv every 6 h. Tigecycline 150 mg
iv every 12 h was also added because of Gram-negative bacilli
growth in subsequent three blood cultures. Despite that
antibiotic modiﬁcation, there was persistence of fever. Blood
cultures grew Gram-negative bacilli, which were identiﬁed as
“Raoultella ornithinolytica”  by matrix-assisted laser desorption
ionization-time of ﬂight mass spectrometry (MALDI-TOF MS)
(Bruker Biotyper) and conﬁrmed by conventional biochemical
tests. MICs of antibiotics were determined by BD Phoenix auto-
mated microbiological system (Becton Dickinson, Sparks, MD,
USA). Amoxicillin–clavulanic acid 1 g PO every 8 h was then
added to the regimen. Clinical response did not ensue and it
was switched to ciproﬂoxacin 400 mg  iv every 12 h according to
the results of antibiotic sensitivity testing (Table 1). The patientwas transferred to the intensive care unit where he died one
week later.
It should be kept in mind that Raoultella ornithinolytica
can be the etiologic agent especially in patients with under-
lying conditions. One of the most important issues is the
multidrug resistant proﬁle of these bacteria. Ten to fourteen
days of treatment with tigecycline, amoxicillin–clavulanic
acid, levoﬂoxacin, and cefmetazole are recommended in the
literature.3–5 However, all of these drugs may fail in some
cases, such as the patient herein reported.
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